5 Results

People

  1. Chin
    Chin
  2. Harding
    Harding
  3. Laccetti
    Laccetti
  4. Larsen
    Larsen
  5. Motzer
    Motzer
  6. O'Reilly
    O'Reilly
  7. Park
    Park
  8. Russo
    Russo
  9. Varghese
    Varghese
  10. Voss
    Voss

Groups

  1. Solid Tumor Oncology Division (5)
  2. Department of Medicine (4)
  3. Genitourinary Oncology Service (3)
  4. Gastrointestinal Oncology Service (2)
  5. CTCR Scholars (1)
  6. Center for Pancreatic Cancer Research (1)
  7. MSK Grad Students (1)
  8. Master of Science in Clinical and Translational Cancer Research (1)
  9. Surgery (1)
  10. Urology (1)
  1. "261-566-9263"
Formats
  1. Meeting Abstract (5)
Groups
  1. Solid Tumor Oncology Division (5)
  2. Department of Medicine (4)
  3. Genitourinary Oncology Service (3)
  4. Gastrointestinal Oncology Service (2)
  5. CTCR Scholars (1)
  6. Center for Pancreatic Cancer Research (1)

More Groups

People
  1. Andrew Laccetti (1)
  2. Anna Varghese (1)
  3. Eileen O'Reilly (1)
  4. James Harding (1)
  5. Kathryn Chin (1)
  6. Martin Voss (1)

More People

Years
  1. 2024 (5)
Publications
  1. Journal of Clinical Oncology (5)
Publishers
  1. American Society of Clinical Oncology (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial
    Meeting Abstract

    Motzer, R. J.; Bex, A.; Russo, P.; Tomita, Y.; Cutuli, H.; Rojas, C.; Gross-Goupil, M.; Schinzari, G.; Melichar, B.; Barthelemy, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world data on treatment of chromophobe renal cell carcinoma
    Meeting Abstract

    Battle, D.; Griffith, M.; Msaouel, P.; Voss, M. H.; Staehler, M. D.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design
    Meeting Abstract

    Kyriakopoulos, C.; Chatta, G. S.; Laccetti, A. L.; Iannotti, N.; Sokolova, A.; Hotte, S. J.; Tutrone, R. F.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma
    Meeting Abstract

    Dayyani, F.; Baretti, M.; Lee, S. S.; He, A. R.; Kim, R. D.; Lin, B. S. L.; Enzler, T.; Al Hallak, M. N.; Ulahannan, S. V.; Davis, S. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers
    Meeting Abstract

    O'Reilly, E. M.; Bauer, T. M.; Borazanci, E. H.; Pelster, M.; Varghese, A. M.; Park, W.; Patel, M. R.; Jameson, G. S.; Larsen, M.; Chin, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save